MARTHA NEWCOMB: Open Payments
NPI 1194331371 · FORT BRANCH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$597 in 33 payments from 10 companies in 2025. Trend: 2023 $445 · 2024 $512 · 2025 $597
Food & beverage: $597
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $182 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $93 |
| Alkermes, Inc. | 5 | $77 |
| Vanda Pharmaceuticals Inc. | 4 | $73 |
| ABBVIE INC. | 4 | $60 |
| Indivior Inc. | 2 | $44 |
| Tris Pharma Inc | 1 | $22 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
| Neurocrine BioSciences, Inc. | 1 | $14 |
| Corium, LLC | 1 | $13 |
Products named: REXULTI, CAPLYTA, ARISTADA, VRAYLAR, HETLIOZ, SUBLOCADE, ABILIFY MAINTENA, Dyanavel XR.
Industry payments across IN — which companies pay providers there.
